G. Steven Burrill

Chief Executive Officer

G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. An early pioneer, Mr. Burrill is one of the original architects of the industry and one of its most avid and sustained developers. He currently serves as Chairman of the Board of Pharmasset (NASDAQ: VRUS) and is a member of the Boards of Directors of Catalyst Biosciences, DepoMed (NASDAQ: DEPO), Intranasal, Phytomedics, Proteogenix, Proventys, Targacept (NASDAQ: TRGT) and XDx. Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide. In 2002, Mr. Burrill was recognized as the biotech investment visionary by the prestigious Scientific American magazine (The Scientific American 50).

Mr. Burrill is a founder and currently serves as the Chairman of the Board of the Foundation for the National Medals of Science and Technology. Additionally, he serves as Chairman of the Board on Campaign for Medical Research as well as Chairman of the San Francisco Mayor’s Biotech Advisory Committee (MAYBAC). Other not-for-profit activities include serving on the Boards of Directors for the Bay Area Science Infrastructure Consortium, BayBio, California Healthcare Institute, The Exploratorium, The Kellogg Center for Biotechnology, Kramden Institute, The National Health Museum, and Research!America. He is an adjunct professor at the University of California, San Francisco; and serves on advisory boards for the MIT Center for Biomedical Innovation, University of Wisconsin, University of Illinois, Purdue University, University of Minnesota, Duke University, Northwestern University, and Carnegie Mellon University.